Clinical research shows 20 mgs daily of novel botanical supports joint health
Iminosugars are an emerging class of biological active carbohydrates
Carson City, Nevada – October 7, 2021 – IminoTech, Inc. announced today that its patented joint health ingredient Q-actin™ has won the 2021 Nutrition Industry Executive award for the Healthy Aging category. Each year the publication honors “the most cutting-edge and advanced natural branded nutritional ingredients backed by science.”
A panel of health and nutrition experts evaluated nominated products in several categories based on the following criteria:
Product Research/Evidence/Bioavailability
Sustainability/Traceability/Certifications (if applicable)
Consumer Need
The “Impressiveness Factor”
“The recognition of Q-actin’s potential to deliver real, science-based joint health benefits to consumers is gratifying,” said Shil Kothari, IminoTech Chief Executive Officer. “We believe this potent new ingredient, with its small daily serving size of only 20 milligrams, will have a significant impact on the healthy aging and joint health product market.”
Q-actin is a natural ingredient clinically tested to support, improve and strengthen joint health. It is an extract sourced from select cucumbers (Cucumis sativus L.) with high levels of an iminosugar called ido-BR1 ((2R,3R,4R,5S)-3,4,5-trihydroxypiperidine-2-carboxylic acid) that increases joint flexibility, function and mobility. Iminosugars are unlike other sugar molecules. A nitrogen atom has replaced the oxygen atom in the ring of the molecular structure. This small change can disrupt or restore certain cellular functions.
Q-actin reduces Tumor Necrosis Factor Alpha (TNF-α), an inflammatory cytokine that can increase metalloproteinases, enzymes that lead to a breakdown in cartilage. Q-actin is believed to work through multiple mechanisms, including the binding to hyaluronic acid receptor (CD44) and inhibiting a sialidase (enzymes that enhance the ability of microorganisms to invade and destroy tissue) involved in the inflammation process.
The award judges found Q-actin’s research and serving size notable. “The fact that it only requires a 20 mg dose and has demonstrated greater efficacy than a considerably higher dose of glucosamine/chondroitin makes Q-actin truly novel,” stated judge Gene Bruno, MS, MHS, RH(AHG), Vice President of Scientific & Regulatory Affairs, Twinlab Consolidation Corporation. Cheryl Myers, Chief Science and Education Officer EuroPharma Inc., maker of Terry Naturally: Q-actin is an “interesting botanical” supported by “good human clinical studies demonstrating safety and benefits.”
Other joint health ingredients (glucosamine/chondroitin, curcuminoids, collagen, eggshell membrane, certain vitamins and minerals) support the building blocks for joint repair but do little to address the inflammation that often causes joint damage. A randomized clinical study demonstrated that Q-actin was significantly more effective than glucosamine-chondroitin in relieving knee pain and increasing mobility in subjects with moderate joint issues. Study participants were evaluated at regular intervals using widely accepted medical evaluation tools (WOMAC, VAS, LFI). The Q-actin group showed significant improvements in function and discomfort over GC at every evaluation period, regardless of the measurement tool. Over six months, for example, Q-actin reduced WOMAC scores 70 percent—twice as much improvement as the GC group.
Products containing Q-actin are available or are in licensing stages in North America, Europe and Asia.
About IminoTech
IminoTech Inc. is a science-based natural products company developing patented natural ingredients called iminosugars for applications in foods, beverages and supplements that support health and wellness. Iminosugars are an emerging class of novel carbohydrates that play an important role in a wide range of biological activities in the body
IminoTech is developing additional iminosugars as functional ingredients with health benefits for regulation of blood sugar, body weight and immune health. Pending the results of clinical studies, the first of these additional products may become available in early 2022. IminoTech is based in Carson City, Nevada, USA.